Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)

Inclusion Criteria:

- Males and females ≥18 years of age

- Participants in the Dose Escalation portion must have one of the following advanced
or recurrent malignancies: gastrointestinal (colorectal or gastric); ovarian;
melanoma; non-small cell lung adenocarcinoma; or bladder.

- Participants in the Monotherapy Expansion Cohort must have one of the following
advanced or recurrent malignancies: cutaneous melanoma showing primary progression
following treatment with an anti-programmed cell death (PD) or anti-PDL1 regimen; or
anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric cancer, including
gastroesophageal junction cancer of Siewert Type II and Type III.

- Participants in the Combination Expansion Cohorts must have one of the following
advanced or recurrent malignancies: non-small cell lung adenocarcinoma or cutaneous
melanoma showing primary progression following treatment with an anti-PD1 or
anti-PD-L1 regimen; or anti-PD1 or anti-PD-L1 treatment-naïve colorectal or gastric
cancer, including gastroesophageal junction cancer of Siewert Type II and Type III.

- Melanoma with BRAF V600E or V600K mutation-positive melanoma must have progressed on,
or were intolerant to, prior BRAF- or MEK-inhibitor therapy

- Must have at least 1 measurable lesion per Response Evaluation Criteria in Solid
Tumors (RECIST) 1.1 with progressing or new tumors since last antitumor therapy

- Must have adequate hematologic, renal, and liver function

- Eastern Cooperative Oncology Group (ECOG) performance status 0-1

- Females must not be pregnant (negative human chorionic gonadotropin test within 72
hours prior to receiving the first dose of study medication) or breastfeeding

- Women of childbearing potential and male participants must agree to use adequate
contraception throughout the study and for up to 180 days after study treatment

- An estimated life expectancy of at least 3 months

- Must consent to provide an archival tumor biopsy sample at any time point from
screening to study exit

- Must consent to allow the acquisition of new tissue biopsy samples during the study

Exclusion Criteria:

- History of severe hypersensitivity reactions or immune related adverse events to
other monoclonal antibodies

- History of other active malignancy within the prior 2 years

- History of insulin-dependent or uncontrolled Diabetes Mellitus

- History of inflammatory bowel disease

- Autoimmune disorders

- Known HIV and/or Hepatitis B or C infections

- Known systemic bleeding or platelet disorder

- Receipt of live vaccines with 4 weeks (28 days) of study

- History or evidence of non-infectious pneumonitis that required steroids or current
pneumonitis